Page 91 - 《中国药房》2024年17期
P. 91
National Health Commission. China health statistics year‐ (22):2415-2420.
book:2022[M]. Beijing:China Union Medical College DAI X F,DU J. Formulation and application effect analy‐
Press,2022:148-153. sis of clinical pharmaceutical pathway for type 2 diabetes
[ 3 ] 中华医学会,中华医学会杂志社,中华医学会全科医学 mellitus under the environment of DRGs[J]. Chin J Hosp
分会,等.稳定性冠心病基层诊疗指南:实践版:2020[J]. Pharm,2022,42(22):2415-2420.
中华全科医师杂志,2021,7(3):274-280. [11] ZENG J Q. The pilot results of 47 148 cases of BJ-DRGs-
Chinese Medical Association, Chinese Medical Journals based payment in China[J] Int J Health Plann Manage,
Publishing House,Chinese Society of General Practice, 2019,34(4):1386-1398.
et al. Guideline for primary care of stable coronary artery [12] 沈哲伦,王佳萍,计建军,等. DRG背景下临床药师合理
disease:practice version:2020[J]. Chin J Gen Pract,2021, 用药管理的效果分析[J]. 实用药物与临床,2023,26(8):
7(3):274-280. 731-734.
[ 4 ] 钟丹,李春明,杨雪,等. 基于彩虹模型的慢性呼吸系统 SHEN Z L,WANG J P,JI J J,et al. Effect analysis of
疾病整合型药学服务模式构建与政策建议[J]. 医药导 clinical pharmacists participating in rational medication
报,2024,10(7):1165-1170. management based on DRG[J]. Pract Pharm Clin Reme-
ZHONG D,LI C M,YANG X,et al. Construction and dies,2023,26(8):731-734.
policy recommendations for an integrated pharmaceutical [13] 伍渊麟,陈世耕,鲜秋婉,等. DRG背景下临床药师参与
care model for chronic respiratory diseases based on the 消化内科药事精细化管理的实践[J]. 中国药房,2022,33
rainbow model[J]. Her Med,2024,10(7):1165-1170. (17):2157-2161.
[ 5 ] 杭永付,徐燕,戴小花,等. 腹膜透析患者全程智慧化药 WU Y L,CHEN S G,XIAN Q W,et al. Practice of clini‐
学服务模式的建立[J]. 中国药房,2023,34(21):2644-2648. cal pharmacists participating in fine management of phar‐
HANG Y F,XU Y,DAI X H,et al. Establishment of maceutical affairs in gastroenterology department based
whole-process intelligent pharmaceutical care model for on DRG data[J]. China Pharm,2022,33(17):2157-2161.
peritoneal dialysis patients[J]. China Pharm,2023,34 [14] 伍渊麟,鲜秋婉,李晨,等. DRG视角下临床药师参与肿
(21):2644-2648. 瘤中心药事精细化管理的实践与思考[J]. 中国药房,
[ 6 ] 林瑶,岳姣,薛晓娟,等. 新型智能交互式药学服务模式 2022,33(22):2801-2806.
的探索与实践[J]. 中国医院药学杂志,2024,10(11): WU Y L,XIAN Q W,LI C,et al. Practice and exploration
1351-1355. of clinical pharmacists participating in refined pharmaceu‐
LIN Y,YUE J,XUE X J,et al. New intelligent interactive tical management of oncology center from the perspective
pharmaceutical care model:exploration and practice[J]. of DRG[J]. China Pharm,2022,33(22):2801-2806.
Chin J Hosp Pharm,2024,10(11):1351-1355. [15] 李黎,朱亚宁,张丹,等 . DRGs 付费模式下临床药师参
[ 7 ] 曹文静,肖灿,张鹏,等. 疾病诊断相关分组背景下基于 与神经内科药品成本管控效果分析[J]. 中国药业,2022,
Ucinet和SOJA法的用药方案优化模式的建立与效果评 31(10):34-38.
价[J]. 中国临床药学杂志,2023,32(6):401-407. LI L,ZHU Y N,ZHANG D,et al. Effect of clinical phar‐
CAO W J,XIAO C,ZHANG P,et al. Establishment and macists on drug cost control in neurology department un‐
effect evaluation of drug regimen optimization model der DRGs payment model[J]. China Pharm,2022,31
based on Ucinet and SOJA methods under the diagnosis (10):34-38.
related group background[J]. Chin J Clin Pharm,2023,32 [16] 国家风湿病数据中心,中国系统性红斑狼疮研究协作
(6):401-407. 组.非甾体消炎药相关消化道溃疡与溃疡并发症的预防
[ 8 ] 贺哲,张杰,翁雨雄,等. DRG支付方式改革下大型公立 与治疗规范建议[J]. 中华内科杂志,2017,56(1):81-85.
医院临床路径实施策略分析[J]. 中国医院管理,2024,44 National Rheumatology Data Center,Chinese Systemic
(4):70-73. Lupus Erythematosus Research Collaboration Group. Re-
HE Z,ZHANG J,WENG Y X,et al. Implementation stra- commendations for the prevention and treatment standards
tegy analysis of clinical pathway in large public hospitals of non steroidal anti inflammatory drug related digestive
under DRG payment reform[J]. Chin Hosp Manag,2024, ulcers and ulcer complications[J]. Chin J Intern Med,
44(4):70-73. 2017,56(1):81-85.
[ 9 ] 胡兆礼,陈姬雅,徐圆圆 . DRG 付费在公立医院的管理 [17] 唐迎迎,朱永超,刘文辉.某院注射用烟酰胺使用情况调
实践与应用思考[J]. 医院管理论坛,2020,37(7):9-11. 查分析[J].上海医药,2022,43(11):50-53.
HU Z L,CHEN J Y,XU Y Y. Discussion on management TANG Y Y,ZHU Y C,LIU W H. Investigation and analy‐
practice and application of DRGs payment in public hospi‐ sis of the use of nicotinamide for injection in a hospital[J].
tals[J]. Hosp Manag Forum,2020,37(7):9-11. Shanghai Med Pharm J,2022,43(11):50-53.
[10] 代雪飞,杜娟. DRGs环境下2型糖尿病临床药学路径制 (收稿日期:2024-04-19 修回日期:2024-06-21)
定及应用成效分析[J]. 中国医院药学杂志,2022,42 (编辑:林 静)
中国药房 2024年第35卷第17期 China Pharmacy 2024 Vol. 35 No. 17 · 2141 ·